|
Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment Free Survival with Immune Checkpoint Inhibitors and Let's talk about the elephant in the room: Hemophagocytic Lymphohistocytosis (HLH) |
11/02/2022 - 8:00am to 9:00am EDT |
|
Tackling resistance in triple negative breast cancer |
11/16/2022 - 8:00am to 9:00am EST |
|
“Cell Therapies for Solid Tumor Malignancies.” and "Global Health & Oncology: Why Should Duke Care?" |
05/11/2022 - 8:00am to 9:00am EDT |
|
“Enhanced dendritic cell vaccine migration and improved overall survival in glioblastoma: Results from a randomized, double-blinded, phase II validation trial (ELEVATE)” |
08/31/2022 - 8:00am to 8:30am EDT |
Facebook
Twitter
LinkedIn
Forward